Tumor News and Research

RSS

NK cells may help limit metastasis in women with breast cancer

The main cause of death in women with breast cancer is spread of the original tumor to distant sites, a process known as metastasis. Immune cells known as NK cells help limit tumor progression and metastasis in animal models.

16 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

MYCN amplification can serve as a favorable prognostic indicator for neuroblastoma

Neuroblastoma, a malignant tumor that primarily affects infants and young children, is a leading cause of death for children with cancer. When amplification of the MYCN oncogene is found in the tumor, it usually indicates an aggressive tumor with rapid progression of the disease and a poor outcome. Thus MYCN amplification has come to be used as a prognostic indicator.

12 Aug 2011

NSAIDs like ibuprofen slow the spread of breast cancers

Published online on Aug. 7, 2011, the journal Nature Medicine reports that non-steroidal anti-inflammatory drugs including ibuprofen reduce the severity of postpartum breast cancers in animal models.

12 Aug 2011

Mayo Clinic, ABTA to establish education program for brain tumor patients

The American Brain Tumor Association (ABTA) and Mayo Clinic are establishing a program to provide educational support for patients coping with the diagnosis and treatment of brain tumors.

12 Aug 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

Paper outlines anticancer drug curaxins' mechanism of action

A paper published today by Science Translational Medicine outlines the process by which a category of anticancer drugs called curaxins inhibit tumor cell growth and division.

11 Aug 2011

Gene therapy to combat leukemia

In a medical breakthrough scientists have found that gene therapy could be used to cure leukemia. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. These genetically modified T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is the most common form of leukemia.

11 Aug 2011

Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek to the U.S. Food and Drug Administration.

11 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Novel therapy shrinks tumors without collateral damage

A potential new option is beginning to emerge for patients with the fastest growing form of cancer in the United States, according to researchers at the University of Alabama at Birmingham.

10 Aug 2011

Health Canada approves Boston Scientific's WallFlex Biliary RX Fully Covered Stent

Boston Scientific Corporation's WallFlex Biliary RX Fully Covered Stent has received Health Canada approval for the treatment of benign biliary strictures, which supplements its current indication for management of malignant biliary strictures.

10 Aug 2011

Simcere second quarter total revenue increases 0.3% to US$84.4 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2011.

9 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

9 Aug 2011

Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study

Senesco Technologies, Inc. today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma.

9 Aug 2011

New Acromegaly clinical practice guidelines

Today the American Association of Clinical Endocrinologists (AACE) released updated Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly.

9 Aug 2011

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

8 Aug 2011

New study supports DNA-based 'biomarker' blood test for prostate cancer screening

A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.

8 Aug 2011